Literature DB >> 10976276

[A polymorphism study of the CYP19 gene in endometrial cancer patients].

L M Bershteĭn1, E N Imianitov, E N Suspitsyn, M Iu Grigor'ev, E P Sokolov, A V Togo, K P Khanson, T E Poroshina, V B Gamaiunova, D A Vasil'ev, A Iu Kovalevskiĭ, O N Volkov.   

Abstract

A strong connection is known to exist between initiation/promotion of endometrial cancer and excess of estrogens. Therefore, participation of certain alleles of genetic polymorphisms in steroid biosynthesis or metabolism may be responsible for predisposition to the disease. The present study, comparing CYP19 (aromatase) gene polymorphism in 85 patients and 110 healthy females, pointed to a more frequent occurrence of relatively longer alleles (A6 and A7) of the CYP19 gene in the former group. Furthermore, precisely those genotypes co-occurred more frequently with elevated blood levels of estradiol and testosterone in postmenopausal patients. Hence, CYP19 gene polymorphism may be regarded as a factor of genetic risk for endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976276

Source DB:  PubMed          Journal:  Vopr Onkol        ISSN: 0507-3758


  1 in total

1.  Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

Authors:  Liewei Wang; Katarzyna A Ellsworth; Irene Moon; Linda L Pelleymounter; Bruce W Eckloff; Yvette N Martin; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Vera J Suman; Saranya Ravi; J Michael Dixon; William R Miller; Eric D Wieben; Aman Buzdar; Richard M Weinshilboum; James N Ingle
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.